Antimetabolites, in particular nucleobase and nucleoside analogues, are cytotoxic drugs
that, starting from the small field of paediatric oncology, in combination with other …

Introduction: Nucleosidic analogs such as pyrimidine and purine derivatives are mainstay in
the field of treating cancers, both in adults and in children. All these drugs act as …

Cytarabine (AraC) represents the most effective single agent treatment for AML.
Nevertheless, overriding AraC resistance in AML remains an unmet medical need. Here we …

Acute myeloid leukemia is a clonal but heterogeneous disease differing in molecular
pathogenesis, clinical features and response to chemotherapy. This latter frequently consists …

Coal plants represent one of the main sources of environmental pollution due to the
combustion process of this mineral and the consequent release of gases and particles …

Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous malignancy
that is primarily treated with combinations of cytarabine and anthracyclines. Although this …

Cytarabine is considered the most effective chemotherapeutic option in acute myeloid
leukemia (AML). The impact of 10 polymorphisms in cytarabine metabolic pathway genes …

Aims Cytidine deaminase (CDA) activity in cancer patients' serum has been proposed as a
predictive biomarker for efficacy and toxicity of nucleoside analogues. However, discrepant …

Background The mechanism behind poor survival of acute myeloid leukemia (AML) patients
with 1-barabinofuranosylcytosine (Ara-C) based treatment remains unclear. This study …

The cytidine deaminase (CDA) catalyzes the irreversible hydrolytic deamination of the
cytarabine (AraC) into a 1-β-D-arabinofuranosyluracil (AraU), an inactive metabolite that …